Short answer
SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on August 3, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature information dated August 3, 2026.
SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature information dated August 3, 2026
- No earnings figures or operating results presented in the provided Item 2.02 text
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue $219.1M, up 32%; growth products revenue $175.7M, up 52%, led by Qelbree, ZURZUVAE, GOCOVRI, and ONAPGO
- Qelbree sales $89.2M, up 15%; prescriptions rose 17%, including 25% adult growth
- ONAPGO sales $13.5M versus $1.6M; second-supplier FDA submission remains targeted for Q3 2026
- GAAP operating loss $58.0M after $54.9M APOKYN impairment; adjusted operating earnings $31.2M versus $40.9M
- 2026 revenue guidance raised to $860M-$890M; adjusted operating earnings guidance raised to $150M-$180M despite GAAP loss outlook of $20M-$50M
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings
Get the next SUPN 8-K as it lands
Follow SUPN for push alerts, or ask the research agent what this filing means.